A Phase II trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis

Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II trial evaluating ruxolitinib and azacitidine combination therapy in patients with myelofibrosis (MF). Of the 61 patients enrolled, 62% of them had higher-risk disease. 45 responded, primarily with reduced spleen size. The median overall survival (OS) was 46 months at a 92-month follow-up. Higher-risk patients who underwent allogeneic stem cell transplantation (alloSCT) showed a trend towards improved progression-free survival (PFS) compared to those who did not have alloSCT. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.